Lofepramine - 97%, high purity , CAS No.23047-25-8, Inhibitor of NET;Inhibitor of SERT

Item Number
L287104
Grouped product items
SKUSizeAvailabilityPrice Qty
L287104-5mg
5mg
3
$92.90
L287104-10mg
10mg
3
$141.90
L287104-25mg
25mg
2
$318.90
L287104-50mg
50mg
2
$574.90
L287104-100mg
100mg
2
$1,034.90

5-HT and NA reuptake inhibitor (SNRI)

Basic Description

Synonyms1-(4-chlorophenyl)-2-{[3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]methylamino}ethanone | Gamanil | HMS3413F21 | Lopramine | J-014957 | DB 2182 | Ethanone, 1-(4-chlorophenyl)-2-[[3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]methylamino]- | Lof
Specifications & PurityMoligand™, ≥97%
Biochemical and Physiological MechanismsSerotonin and noradrenalin re-uptake inhibitor (SNRI) that is metabolized to desipramine. Produces inhibition of liver tryptophan pyrollase activityin vitroand displays antidepressant propertiesin vivo.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of NET;Inhibitor of SERT
Product Description

Product Describtion:

Lofepramine (Lopramine) is a potent tricyclic antidepressant and is extensively metabolised to Desipramine. The antidepressant activity of Lofepramine stems from the facilitation of noradrenergic neurotransmission by uptake inhibition. Lofepramine may also potentiate serotoninergic neurotransmission by inhibition of the neuronal uptake of serotonin and the enzyme tryptophan pyrrolase. Lofepramine has significant anxiolytic efficacy in addition to its antidepressant properties.

AI Insight

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

Pubchem Sid488179810
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488179810
IUPAC Name 1-(4-chlorophenyl)-2-[3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl-methylamino]ethanone
INCHI InChI=1S/C26H27ClN2O/c1-28(19-26(30)22-13-15-23(27)16-14-22)17-6-18-29-24-9-4-2-7-20(24)11-12-21-8-3-5-10-25(21)29/h2-5,7-10,13-16H,6,11-12,17-19H2,1H3
InChi Key SAPNXPWPAUFAJU-UHFFFAOYSA-N
Canonical SMILES CN(CCCN1C2=CC=CC=C2CCC3=CC=CC=C31)CC(=O)C4=CC=C(C=C4)Cl
Isomeric SMILES CN(CCCN1C2=CC=CC=C2CCC3=CC=CC=C31)CC(=O)C4=CC=C(C=C4)Cl
PubChem CID 3947
Molecular Weight 418.97

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

10 results found

Lot NumberCertificate TypeDateItem
F2330735Certificate of AnalysisApr 27, 2023 L287104
F2330736Certificate of AnalysisApr 27, 2023 L287104
F2330740Certificate of AnalysisApr 27, 2023 L287104
F2330741Certificate of AnalysisApr 27, 2023 L287104
F2330742Certificate of AnalysisApr 27, 2023 L287104
F2330743Certificate of AnalysisApr 27, 2023 L287104
F2330744Certificate of AnalysisApr 27, 2023 L287104
F2330746Certificate of AnalysisApr 27, 2023 L287104
F2330747Certificate of AnalysisApr 27, 2023 L287104
F2330755Certificate of AnalysisApr 27, 2023 L287104

Safety and Hazards(GHS)

Pictogram(s) GHS08,   GHS07
Signal Danger
Hazard Statements

H373:Causes damage to organs through prolonged or repeated exposure

H336:May cause drowsiness or dizziness

H370:Causes damage to organs

Precautionary Statements

P261:Avoid breathing dust/fume/gas/mist/vapors/spray.

P321:Specific treatment (see ... on this label).

P405:Store locked up.

P501:Dispose of contents/container to ...

P264:Wash hands [and …] thoroughly after handling.

P260:Do not breathe dust/fume/gas/mist/vapors/spray.

P271:Use only outdoors or in a well-ventilated area.

P270:Do not eat, drink or smoke when using this product.

P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing.

P403+P233:Store in a well-ventilated place. Keep container tightly closed.

P308+P316:IF exposed or concerned: Get emergency medical help immediately.

P319:Get medical help if you feel unwell.

Related Documents

Reviews

Customer Reviews

References

1. Sánchez C, Hyttel J.  (1999)  Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding..  Cell Mol Neurobiol,  19  (4): (467-89).  [PMID:10379421] [10.1021/op500134e]
2. Tatsumi M, Groshan K, Blakely RD, Richelson E.  (1997)  Pharmacological profile of antidepressants and related compounds at human monoamine transporters..  Eur J Pharmacol,  340  (2-3): (249-58).  [PMID:9537821] [10.1021/op500134e]

Solution Calculators